Alnylam's longer-term RNAi treatment lowers blood pressure in mid-stage study - Endpoints News
endpts.comSubmitted by endpointsnews6292 in news
One to two doses of an RNA interference treatment developed by Alnylam Pharmaceuticals reduced blood pressure for six months in a mid-stage clinical trial, according to new research presented this weekend at a medical meeting. Alnylam’s goal is to develop the…